Previous 10 | Next 10 |
- Fifth Dose Level Cohort of GFH009, a Highly Selective CDK9 Inhibitor, Initiated - - No Dose-Limiting Toxicities in First Four Dose Levels - NEW YORK, April 11, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the ...
Rona Therapeutics, a Shanghai RNA company founded last year, completed a $33 million Series A financing to build a delivery platform and initial therapeutic pipeline. Suzhou Kintor Pharma reported proxalutamide was 100% effective as a COVID-19 therapy in a US Phase III trial in preven...
Sellas Life Sciences (NASDAQ:SLS) said China’s National Medical Products Administration accepted an application for starting the first clinical trial of potential cancer drug 3D189 in China. The investigational new drug application for a small phase 1 trial of 3D189 was filed earl...
NEW YORK, April 06, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, tod...
– In-licensed Next-Generation, Highly Selective CDK9 Inhibitor – – Closed Underwritten Public Offering with Gross Proceeds of $25 Million – – Appointed Robert Francomano as Chief Commercial Officer –...
Gainers: Weidai (WEI) +68%. Manning & Napier (MN) +41%. Chicken Soup for the Soul Entertainment (CSSE) +28%. Hudson Capital (HUSN) +26%. Guardforce AI (GFAI) +19%. U.S. Xpress Enterprises (USX) +20%. Blackboxstocks (BLBX) +17%. Takung Art (TKAT) +17%. Borr Drilling (BORR) +17%. Clever Lea...
Gainers: ORIC Pharmaceuticals (ORIC) +14%. Unity Biotechnology (UBX) +13%. Applied Therapeutics (APLT) +11%. Genetron (GTH) +11%. Clarus Therapeutics (CRXT) +8%. Losers: SELLAS Life Sciences SLS -39%. Pulse Biosciences (PLSE) -22%. Spero Therapeutics SPRO...
SELLAS Life Sciences (NASDAQ:SLS) plunged 23.7% premarket after it priced its earlier announced underwritten public offering of 4.63M shares and accompanying warrants at combined public offering price of $5.40/share. The warrants to purchase shares are immediately exercisable a...
NEW YORK, March 31, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, tod...
Sellas Life Sciences (NASDAQ:SLS) on Thursday signed an exclusive license agreement with China's GenFleet Therapeutics (Shanghai) to develop and commercialize a highly selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor worldwide outside of Greater China. Sellas will pay ...
News, Short Squeeze, Breakout and More Instantly...
SELLAS Life Sciences Group Inc. Company Name:
SLS Stock Symbol:
NASDAQ Market:
SELLAS Life Sciences Group Inc. Website:
2024-07-19 10:10:00 ET July 19, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech, Cleantech Sectors. The newest biotech companies are involved in blood disorder treat...
- Acute Myeloid Leukemia (AML) is the Second Most Common Hematological Malignancy in Children Often Associated with Poorer Prognosis Compared to Other Pediatric Cancers – - This Recognition Marks SELLAS’ Second RPDD Following the Designation for ALL Received Last Month - -...
NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today ...